Related Experiment Videos
Tachykinin dysfunction attenuates monocrotaline-induced pulmonary hypertension
1Department of Physiology, National Taiwan University College of Medicine, 100, Taipei, Taiwan.
Toxicology and Applied Pharmacology
|March 29, 2003
Summary
Tachykinins contribute to pulmonary hypertension. Blocking tachykinin gene expression with RNA interference (RNAi) or neurokinin (NK) receptor antagonists reduced pulmonary hypertension markers in rats. This suggests targeting tachykinins may treat this condition.
Area of Science:
- Pharmacology
- Molecular Biology
- Cardiovascular Research
Background:
- Pulmonary hypertension is a severe condition characterized by high blood pressure in the pulmonary arteries.
- Tachykinins, a family of neuropeptides, and their receptors are implicated in cardiovascular regulation, but their specific role in pulmonary hypertension remains unclear.
- Monocrotaline (MCT) is a known toxin that induces experimental pulmonary hypertension, serving as a model for studying the disease.
Purpose of the Study:
- To investigate the role of tachykinins in monocrotaline (MCT)-induced pulmonary hypertension.
- To evaluate the efficacy of RNA interference (RNAi) targeting preprotachykinin (PPT) gene expression and neurokinin (NK) receptor antagonists in attenuating MCT-induced pulmonary hypertension.
Main Methods:
- Experimental pulmonary hypertension was induced in rats using a single injection of monocrotaline (MCT).
- RNA interference (RNAi) using double-stranded PPT (ds PPT) RNA was administered to reduce PPT gene expression.
- Rats were treated with neurokinin (NK) receptor antagonists (NK1 and NK2) or their inactive enantiomers, and physiological parameters were assessed.
Main Results:
- MCT administration led to significant right ventricular hypertrophy, increased pulmonary arterial pressure, elevated PPT mRNA levels, and increased substance P in lung tissue.
- Both RNAi targeting PPT and treatment with NK receptor antagonists significantly attenuated these MCT-induced pathological changes.
- The observed effects were specific, as inactive enantiomers did not produce similar protective outcomes.
Conclusions:
- Tachykinins play a crucial role in the development and progression of MCT-induced pulmonary hypertension.
- Downregulating tachykinin expression via RNAi or blocking NK receptors offers a potential therapeutic strategy for pulmonary hypertension.
- These findings highlight the therapeutic potential of targeting the tachykinin system in managing pulmonary hypertension.